Viking Therapeutics, Inc. Increase (Decrease) in Other Accrued Liabilities
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2022-10-26
- Viking Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2022-09-30 was $2.10M.
- Viking Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2022-06-30 was $523.00K, a 22.40% decline year-over-year.
- Viking Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2022-03-31 was $694.00K.
- Viking Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2021-09-30 was -$77.00K, a 106.95% decline year-over-year.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month |
|---|---|---|---|
| 2022-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $2.62M derived: sum of 2 quarters · filed 2022-10-26 | $3.31M 10-Q · filed 2022-10-26 |
| 2022-06-30 | $523.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $1.22M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $694.00K 10-Q · filed 2022-04-27 | ||
| 2021-09-30 | -$77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $597.00K derived: sum of 2 quarters · filed 2022-10-26 | $575.00K 10-Q · filed 2022-10-26 |
| 2021-06-30 | $674.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $652.00K 10-Q · filed 2022-07-27 | |
| 2021-03-31 | -$22.00K 10-Q · filed 2022-04-27 | ||
| 2020-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.50M derived: sum of 2 quarters · filed 2021-11-03 | $2.59M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $392.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $1.48M 10-Q · filed 2021-07-28 | |
| 2020-03-31 | $1.09M 10-Q · filed 2021-04-28 | ||
| 2019-09-30 | $181.00K 10-Q · filed 2020-10-28 |